Reverse translation of failed treatments can help improving the validity of preclinical animal models

被引：10
|
作者：
't Hart, Bert A. [1 ,2 ]
机构：
[1] Biomed Primate Res Ctr, Dept Immunobiol, NL-2288 GJ Rijswijk, Netherlands
[2] Univ Groningen, Univ Med Ctr Groningen, Dept Neurosci, Groningen, Netherlands
来源：
EUROPEAN JOURNAL OF PHARMACOLOGY | 2015年 / 759卷
关键词：
Animal models; Non-human primate; EAE; Autoimmune; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; B-CELL DEPLETION; CD8(+) T-CELLS; MULTIPLE-SCLEROSIS; DOUBLE-BLIND; COMMON MARMOSET; PHASE-II; ANTIBODY; EAE; DISEASE;
D O I：
10.1016/j.ejphar.2015.03.030
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
A major challenge in translational research is to reduce the currently high proportion of new candidate treatment agents for neuroinflammatory disease, which fail to reproduce promising effects observed in animal models when tested in patients. This disturbing situation has raised criticism against the currently used animal models in preclinical research and calls for improvement of these models. This seems a difficult task as the cause of failure is often not known. Here we propose a potentially useful strategy for investigating why a promising strategy fails as a guidance for improving the validity of the animal model(s). (C) 2015 Elsevier B.V. All rights reserved.
引用
收藏
页码：14 / 18
页数：5
相关论文
共 13 条
  • [1] Improvement of preclinical animal models for autoimmune-mediated disorders via reverse translation of failed therapies
    't Hart, Bert A.
    Jagessar, S. Anwar
    Kap, Yolanda S.
    Haanstra, Krista G.
    Philippens, Ingrid H. C. H. M.
    Serguera, Che
    Langermans, Jan
    Vierboom, Michel
    DRUG DISCOVERY TODAY, 2014, 19 (09) : 1394 - 1401
  • [2] Improving translation of animal models of addiction and relapse by reverse translation
    Venniro, Marco
    Banks, Matthew L.
    Heilig, Markus
    Epstein, David H.
    Shaham, Yavin
    NATURE REVIEWS NEUROSCIENCE, 2020, 21 (11) : 625 - 643
  • [3] Reverse Translation for Assessment of Confidence in Animal Models of Multiple Sclerosis for Drug Discovery
    't Hart, Bert A.
    Laman, Jon D.
    Kap, Yolanda S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 (02) : 262 - 270
  • [4] Editorial: Verification of Animal Pain Models by Reverse Translation
    Caudle, Robert M.
    Smith, Maree Therese
    Romero-Sandoval, E. Alfonso
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [5] Editorial: Preclinical animal models and measures of pain: improving predictive validity for analgesic drug development - volume II
    Tappe-Theodor, Anke
    Martin, Thomas J.
    Negus, S. Stevens
    FRONTIERS IN PAIN RESEARCH, 2025, 5
  • [6] Epilepsy Comorbidities: How Can Animal Models Help?
    Stafstrom, Carl E.
    ISSUES IN CLINICAL EPILEPTOLOGY: A VIEW FROM THE BENCH, 2014, 813 : 273 - 281
  • [7] Can animal models help to explore functions of nanoparticles in health and diseases?
    Dong, Caijuan
    Shang, Lijun
    NANOMEDICINE, 2024, 19 (03) : 181 - 183
  • [8] Can acupuncture reverse oxidative stress and neuroinflammatory damage in animal models of vascular dementia?: A preclinical systematic review and meta-analysis
    Wen, Qin
    Hong, Xueqin
    He, Kunze
    Liu, Buping
    Li, Min
    MEDICINE, 2023, 102 (23)
  • [9] Animal models to study pathogenesis and treatments of cardiac disorders in rheumatoid arthritis: Advances and challenges for clinical translation
    Kessler, Julie
    Totoson, Perle
    Devaux, Sylvie
    Moretto, Johnny
    Wendling, Daniel
    Demougeot, Celine
    PHARMACOLOGICAL RESEARCH, 2021, 170
  • [10] Animal models of Aspergillus infection in preclinical trials, diagnostics and pharmacodynamics:: What can we learn from them?
    Clemons, Karl V.
    Stevens, David A.
    MEDICAL MYCOLOGY, 2006, 44 : S119 - S126
12